Pien Tze Huang inhibits the proliferation of human colon carcinoma cells by arresting G1/S cell cycle progression

Introduction

Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in Western societies (1). Despite recent advances in CRC treatment, 5-fluorouracil (5-FU)-based regimens continue to be the international standard chemotherapy for patients with advanced CRC (2). However, drug resistance profoundly limits the effectiveness of current CRC cancer chemotherapies (3). Moreover, application of 5-FU-based regimens is often coupled with serious toxicity and side-effects such as anemia, leucopenia, thrombocytopenia and peripheral neuropathy (4,5). Therefore, it is essential to develop safer agents for the chemotherapeutic treatment of CRC. Traditional Chinese medicine (TCM), which has relatively few side-effects, plays an important role in primary health care in China and has recently been recognized by Western countries as a key source for revealing novel lead molecules for modern drug discovery. Clinical practice has also shown that many traditional Chinese medicines possess antitumor activities, which provide insight into new therapeutic strategies for cancer treatment (6–14).

Cancer cells are characterized by an uncontrolled increase in cell proliferation (15). Eukaryotic cell proliferation is primarily regulated by the cell cycle. G1/S transition is one of the two main checkpoints of the cell cycle (16), which is responsible for initiation and completion of DNA replication. G1/S progression is strongly regulated by Cyclin D1, which exerts its function by forming an active complex with its major catalytic partners, such as CDK4 (17). An unchecked or hyperactivated Cyclin D1/CDK4 complex often leads to uncontrolled cell division and malignancy (18–21). Therefore, inhibiting excessive proliferation of tumor cells by blocking Cyclin D1/CDK4-mediated G1/S progression is one of the key approaches for the development of anticancer drugs.

Pien Tze Huang (PZH) is a well-known traditional Chinese formula that was first prescribed 450 years ago in the Ming Dynasty, with properties of heat-clearing and detoxification (22). In the TCM system, accumulation of toxic dampness and heat is a major pathogenic factor of cancer, therefore clearing heat and detoxification is a principle of anticancer treatment. For this reason, PZH has been used in China and Southeast Asia for centuries as a folk remedy for various types of cancer. Modern pharmacological studies have proposed that PZH exhibits therapeutic effects in clinical trials of tumors, such as hepatocellular carcinoma and colon cancer (23,24). In addition, in experimental animals PZH inhibits the growth of Ehrlich-Ascites tumor, gastric carcinoma, and hepatoma (25). Moreover, we recently reported that PZH is able to inhibit colon cancer growth both in vivo and in vitro via the promotion of apoptosis and inhibition of tumor angiogenesis (26–28). To elucidate the mechanism of the tumoricidal activity of PZH, we evaluated its effect on the proliferation of the human colon carcinoma cell line Caco-2 and investigated the underlying molecular mechanism.

Materials and methods

Materials and reagents

RPMI-1640, fetal bovine serum (FBS), penicillin-streptomycin, Trypsin-EDTA, and TRIzol reagent were purchased from Invitrogen (Carlsbad, CA, USA). SuperScript II reverse transcriptase was obtained from Promega (Madison, WI, USA). Cyclin D1, CDK4 and β-actin antibodies, and horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Cell Signaling (Beverly, MA, USA). Any other chemicals, unless otherwise stated, were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Preparation of PZH

PZH was obtained from and authenticated by the sole manufacturer Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., China (Chinese FDA approval no. Z35020242). Stock solution of PZH was prepared imme diately prior to use by dissolving the PZH powder in phosphate-buffered saline (PBS) to a concentration of 20 mg/ml. The working concentrations of PZH were obtained by diluting the stock solution in the culture medium.

Cell culture

Human colon carcinoma Caco-2 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Caco-2 cells were grown in RPMI-1640 containing 10% (v/v) FBS, and 100 U/ml penicillin and 100 μg/ ml streptomycin. Cells were cultured at 37°C, in a 5% CO2 humidified environment.

Assessment of cell viability

Cell viability was assessed by MTT colorimetric assay. Caco-2 cells were seeded into 96-well plates at a density of 5×103 cells/well in 0.1 ml medium. The cells were treated with various concentrations of PZH for different periods of time. At the end of the treatment, 100 μl MTT (0.5 mg/ml in PBS) were added to each well, and the samples were incubated for an additional 4 h at 37°C. The purple-blue MTT formazan precipitate was dissolved in 100 μl DMSO. The absorbance was measured at 570 nm using an ELISA reader (BioTek, Model ELX800, USA).

Colony formation

Caco-2 cells were seeded into 6-well plates at a density of 1×105 cells/well in 2 ml medium. After treatment with various concentrations of PZH for 24 h, the cells were collected and diluted in fresh medium in the absence of PZH and then reseeded into 6-well plates at a density of 1×103 cells/well. Following incubation for 8 days in a 37°C humidified incubator with 5% CO2, the formed colonies were fixed with 10% formaldehyde, stained with 0.01% crystal violet and counted. Cell survival was calculated by normalizing the survival of the control cells as 100%.

Cell cycle analysis

The cell cycle analysis was carried out by flow cytometry using a fluorescence-activated cell sorting (FACS) Calibur (Becton-Dickinson, San Jose, CA, USA) and propidium iodide (PI) staining. Subsequent to treatment with various concentrations of PZH for 24 h, Caco-2 cells were collected and adjusted to a concentration of 1x106 cells/ml, and fixed in 70% ethanol at 4°C overnight. The fixed cells were washed twice with cold PBS, and then incubated for 30 min with RNase (8 μg/ml) and PI (10 μg/ml). The fluorescent signal was detected through the FL2 channel and the proportion of DNA in different phases was analyzed using ModfitLT version 3.0 (Verity Software House, Topsham).

RT-PCR analysis

Caco-2 cells were seeded into 6-well plates at a density of 1×105 cells/well in 2 ml medium and treated with various concentrations of PZH for 24 h. Total RNA was isolated with TRIzol reagent. Oligo(dT)-primed RNA (1 μg) was reverse-transcribed with SuperScript II reverse transcriptase (Promega) according to the manufacturer’s instructions. The obtained cDNA was used to determine the mRNA amount of Cyclin D1 and CDK4 by PCR. GAPDH was used as an internal control. The primer sequences used for the amplification of Cyclin D1, CDK4 and GAPDH transcripts were: Cyclin D1, forward: 5′-TGG ATG CTG GAG GTC TGC GAG GAA -3′ and reverse: 5′-GGC TTC GAT CTG CTC CTG GCA GGC-3′; CDK4, forward: 5′-CAT GTA GAC CAG GAC CTA AGC-3′ and reverse: 5′-AAC TGG CGC ATC AGA TCC TAG-3′; GAPDH, forward: 5′-CG ACC ACT TTG TCA AGC TCA-3′ and reverse: 5′-AG GGG TCT ACA TGG CAA CTG-3′. Samples were analyzed by gel electrophoresis (1.5% agarose). The DNA bands were examined using a Gel Documentation System (BioRad, Model Gel Doc 2000, USA).

Western blotting

Caco-2 cells (2.5×105 cells/well) were seeded into 25 cm2 flasks in 5 ml medium. Cells were treated with various concentrations of PZH for 24 h and then lysed with mammalian cell lysis buffer containing protease and phosphatase inhibitor cocktails. The lysates were resolved in 12% SDS-PAGE gels and electroblotted. The PVDF membranes were blocked with 5% skimmed milk and probed with primary antibodies against CyclinD1, CDK4 and β-actin (1:1,000) overnight at 4°C and then with appropriate HRP-conjugated secondary antibody followed by enhanced chemiluminescence detection.

Statistical analysis

Data were analyzed using the SPSS package for Windows (Version 11.5). Statistical analysis of the data was performed using the Student’s t-test and one-way ANOVA. Differences with P<0.05 were considered statistically significant.

Results

PZH inhibits the proliferation of Caco-2 cells

The viability of Caco-2 cells was determined by MTT assay to compare the relative number of cells in PZH-treated monolayers to untreated controls. As shown in Fig. 1A, treatment with 0.25–1 mg/ml of PZH for 24 h dose-dependently reduced cell viability by 11–35% compared to the untreated control cells (P<0.05). We also evaluated the effect of 1 mg/ml of PZH on cell viability with incubation for different periods of time. As shown in Fig. 1B, PZH treatment led to a gradual decrease in cell viability with the increase of exposure time. To verify these results, we examined the effect of PZH on Caco-2 cell survival using a colony formation assay. As shown in Fig. 2A and B, PZH treatment dose-dependently reduced the cell survival rate by 15–52% compared to the untreated control cells (P<0.05). Taken together, these data suggest that PZH inhibits Caco-2 cell proliferation in a dose- and time-dependent manner.

Figure 1. Effect of PZH on Caco-2 cell viability. (A) Caco-2 cells were treated with the indicated concentrations of PZH for 24 h. (B) Cells were treated with 1 mg/ml of PZH for the indicated time periods. Cell viability was determined by the MTT assay. The data were normalized to the viability of control cells. Data are averages with SD (error bars) from at least three independent experiments. *P<0.05 vs. control cells.

Figure 2. Effect of PZH on Caco-2 cell survival. (A) Cells were treated with the indicated concentrations of PZH for 24 h. Cell survival was determined by colony formation analysis. Images are representative of three independent experiments. (B) Quantification of colony formation analysis. The data were normalized to the survival of control cells and are shown as averages with SD (error bars) from at least three independent experiments. *P<0.05 vs. control cells.

PZH blocks G1/S progression of Caco-2 cells

The effect of PZH on the G1 to S progression in Caco-2 cells by PI staining, followed by FACS analysis. Subsequent to treatment with 0, 0.25, 0.5 and 1 mg/ml of PZH the percentage of S-phase cells was found to be 24.0, 15.0, 10.59 and 4.11%, respectively (P<0.05) (Fig. 3), indicating that the inhibitory effect of PZH on Caco-2 cell proliferation is correlated with the arrest of G1/S cell cycle progression.

Figure 3. Effect of PZH on the cell cycle progression in Caco-2 cells. Cells were treated with the indicated concentrations of PZH for 24 h, stained with PI, and analyzed by FACS. The proportion of DNA in the S-phase was calculated using ModfitLT version 3.0 Software. Data shown are averages with SD (error bars) from three independent experiments. *P<0.05 vs. control cells.

PZH regulates the expression of Cyclin D1 and CDK4 in Caco-2 cells

To explore the mechanism of the anti-proliferative activity of PZH, we performed RT-PCR and western blotting to respectively examine the mRNA and protein expression of Cyclin D1 and CDK4 in Caco-2 cells. As shown in Fig. 4, PZH treatment profoundly and dose-dependently reduced the expression of Cyclin D1 and CDK4, at both the transcriptional and translational levels.

Figure 4. Effect of PZH on the expression of Cyclin D1 and CDK4 in Caco-2 cells. Cells were treated with the indicated concentrations of PZH for 24 h. (A) The mRNA levels of Cyclin D1 and CDK4 in PZH-treated and untreated cells were determined by RT-PCR. (B) The protein expression levels of Cyclin D1 and CDK4 were analyzed by western blotting. GAPDH and β-actin were used as the internal controls for the RT-PCR or western blotting assays, respectively. Data are representative of three independent experiments.

Discussion

Drug resistance and toxicity against normal cells limit the effectiveness of current cancer chemotherapies, including those used to treat colorectal cancer (3–5), emphasizing the need for the development of novel cancer chemotherapies. Natural products have received a lot of attention due to their relatively few side-effects compared to modern chemotherapeutics and have been used clinically for thousands of years as important alternative remedies for various diseases, including cancer (6,7). PZH a well-known traditional Chinese formula, first prescribed 450 years ago in the Ming Dynasty, has long been used in China for cancer treatment (22–24). Although it has been shown that PZH inhibits colon cancer growth via the induction of apoptosis and inhibition of tumor angiogenesis (26–28), the precise mechanism of its anticancer effect remains largely unclear. Therefore, in order for PZH to be developed further as an anticancer agent, its underlying molecular mechanism of action should be elucidated.

Cancer cells are characterized by an uncontrolled proliferation (15). Therefore, inhibiting excessive proliferation of tumor cells is one of the key approaches for the development of anticancer drugs. Using MTT and colony formation analyses, we demonstrated that PZH inhibited the proliferation of human colon carcinoma Caco-2 cells, in a dose- and time-dependent manner. Eukaryotic cell proliferation is primarily regulated by the cell cycle. G1/S transition is one of the two main checkpoints of the cell cycle, responsible for initiation and completion of DNA replication (16). By using FACS analysis with PI staining, we found that PZH dose-dependently repressed the G1 to S transition in Caco-2 cells. G1/S progression is tightly regulated by the pro-proliferative Cyclin D1 and CDK4 (17). Overexpression of Cyclin D1 and CDK4 is commonly detected in various types of cancer (18–21). Consistent with the inhibitory effect of PZH on G1/S transition, our data indicated that PZH treatment suppressed the mRNA and protein expression of Cyclin D1 and CDK4 in Caco-2 cells. In conclusion, the present study has demonstrated for the first time that PZH inhibited cancer cell proliferation by blocking G1 to S progression, which may be one of the mechanisms mediating its antitumor activity.

Abbreviations:

Acknowledgements

This study was sponsored by the National Natural Science Foundation of China (no. 81073097), the Developmental Fund of Chen Keji Integrative Medicine (no. CKJ 2011001), and the China Postdoctoral Science Foundation (no. 2012M511437).

References